Swainsonine (Synthetic)
Share product
- structure.search.product.name Swainsonine (Synthetic)
- Produktcode: TRC-S885000
- CAS-Nummer: 72741-87-8
- Marke: TRC
Product Overview
Produkt-Code
TRC-S885000
CAS-Nummer
Produktformat
Neat
Molekularformel
C8 H15 N O3
Molekulargewicht
173.21
Produktkategorien
Alkaloids, TRC, Enzyme inhibitors, Additional Cancer Bioactive Molecules, Additional Neuro Products
Produkttyp
Bioactive Small MoleculePurity
>95% (HPLC)
Dokumentation
Suchen Sie eine andere Chargennummer?
Um alle Analyse-Zertifikate sofort anzuzeigen, melden Sie sich bitte in Ihrem Konto an
oder
E-Mail-Download-Link
{{ errors[0] }}
{{ errors[0] }}
Informationen über unsere Datenverarbeitung finden Sie in unserer Datenschutzerklärung.
Bitte geben Sie Ihre E-Mail-Adresse ein und wir senden Ihnen das relevante Analysezertifikat für die folgenden Chargen per E-Mail zu:
{{ coaPopupData.packSize.coaSelectedLotNumbers }}
{{ errors[0] }}
Wir senden das Analysezertifikat an Ihre E-Mail-Adresse {{ coaEmailPopupData.userEmail }}
Your request has been sent to our sales team to process.
Hier finden Sie ein Sicherheitsdatenblatt für Ihre Region
{{ errors[0] }}
{{ errors[0] }}
Informationen über unsere Datenverarbeitung finden Sie in unserer Datenschutzerklärung.
Your request has been sent to our sales team to process.
Produktinformationen
Chemical Data
Analytenname
Swainsonine
CAS-Nummer
72741-87-8
Molekularformel
C8 H15 N O3
Molekulargewicht
173.21
Genaue Masse
173.1052
SMILES
O[C@@H]1CCCN2C[C@@H](O)[C@@H](O)[C@@H]12
InChI
InChI=1S/C8H15NO3/c10-5-2-1-3-9-4-6(11)8(12)7(5)9/h5-8,10-12H,1-4H2/t5-,6-,7-,8-/m1/s1
IUPAC
(1S,2R,8R,8aR)-1,2,3,5,6,7,8,8a-octahydroindolizine-1,2,8-triol
Produktdaten
Lagertemperatur
-20°C
Versandtemperatur
Room Temperature
Herkunftsland
CANADA
Produkttyp
Bioactive Small Molecule
Produktformat
Neat
Purity
>95% (HPLC)
Product Description
Swainsonine is a plant alkaloid derived from Swainsona canescens (a leguminous plant). It is a reversible, active-site directed inhibitor of a-mannosidase at concentrations of 5-10mM. At acid pH, swainsonine resembles an intermediate in the hydrolysis of mannosidases.Swainsonine completely inhibits mammalian Golgi a-mannosidase II (a-3/6-mannosidase in the glycoprotein processing pathway) and mammalian lysosomal a-mannosidase (acid mannosidase). At higher concentrations, swainsonine also inhibits mammalian cytosolic a-mannosidase. It has been shown to inhibit growth of transformed fibroblasts in soft agar and to enhance the antiproliferative effects of INF on murine lymphoreticular tumor cells in vitro. It also blocks the expression of b1-6 branched complex-type oligosaccharides and shunts the pathway towards hybrid-type oligosaccharides. Swainsonine does not appear to inhibit secretion or expression of glycoproteins at the cell surface. Swainsonine is stable for at least 24 h at 37oC in culture media at physiological pH. Working concentration range is 17-1700 ng/ml (0.1-10mM). Swainsonine (at 1 mg/ml) is not cytotoxic and does not inhibit the growth of a variety of mammalian cell lines. Concentrations required to inhibit Golgi a-mannosidase II in vivo may be somewhat higher, as swainsonine tends to concentrate in the acid environment of cell lysosomes, where it exists as a charged cation and does not permeate through membranes readily.Swainsonine blocks the processing of high-mannose oligosaccharides to complex oligosaccharides. Glycoproteins synthesized in the presence of swainsonine tend to carry mostly high-mannose and hybrid oligosaccharide chains. With short treatments (<24 h) with the inhibitor, cells may retain some complex glycoproteins due to asynchronous cell growth and glycoprotein synthesis.
References: J. Biol. Chem., 258, 7578-7585 (1983), Methods Enzymol., 98, 135 (1983), EMBO Journal, 3, 551-556 (1984), Mol. Cell. Biol., 5, 3467-3475 (1985), Int. J. Cancer, 44, 685 (1989),Melanoma Res., 1, 43 (1991), Bonay, P., & Fresno, M.: Glycobiology, 9(5), 423-433 (1999), Klein, J-LD, et al.: Br. J. of Cancer, 80(1/2), 87-95 (1999)
{{ errors[0] }}